ABSTRACT

Introduction

Health technology assessment (HTA) is a widely used process to systematically evaluate the properties, effects, and impacts of health technology, with the main purpose of informing policymaking in healthcare. However, to ensure optimal use of scarce healthcare budgets, there is a need to look beyond HTA – to post-reimbursement health technology management (HTM).

Areas Covered

This review aims to describe the significant impact HTA, in combination with HTM, has made to the cost-effective prescribing and cost-containment in Ireland. This review will cover a number of specific examples, such as; specific reimbursement criteria for sacubitril/valsartan (Entresto®) and evolocumab (Repatha®), the introduction of a reimbursement application system for lidocaine 5% medicated plaster (Versatis®), and the introduction of ‘preferred’ biosimilars for patent-expired biologic medicines.

Expert Opinion

Healthcare payers are increasingly recognizing the benefits of HTM particularly when used in conjunction with HTA. This review highlights several examples whereby significant cost-savings can be made through HTM of not only new drugs but also drugs which are already available on the market.

中文翻译：

---

结合卫生技术评估和卫生技术管理，提供具有成本效益的处方和成本控制——爱尔兰的经验。

摘要

介绍

卫生技术评估 (HTA) 是一种广泛使用的过程，用于系统地评估卫生技术的特性、效果和影响，其主要目的是为医疗保健决策提供信息。然而，为了确保最佳利用稀缺的医疗保健预算，有必要超越 HTA，转向报销后的医疗技术管理 (HTM)。

涵盖的领域

本综述旨在描述 HTA 与 HTM 相结合对爱尔兰具有成本效益的处方和成本控制的重大影响。本次审查将涵盖许多具体示例，例如：sacubitril/valsartan (Entresto®) 和 evolocumab (Repatha®) 的具体报销标准，引入 5% 利多卡因药膏 (Versatis®) 的报销申请系统，以及为专利过期的生物药物引入“首选”生物仿制药.

专家意见

医疗保健支付者越来越认识到 HTM 的好处，尤其是与 HTA 结合使用时。这篇综述重点介绍了几个例子，通过 HTM 不仅可以为新药而且还可以通过市场上已有的药物显着节省成本。